Fig. 7From: Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivoDFX downregulated the genes in pancreatic adenocarcinoma signaling. A total of six tumors, three tumors from mice treated with 200 mg/kg oral DFX, and three tumors from the controls, were chosen to examine gene expression alternation. A total of 2412 genes differentially expressed with a significance cutoff of p <0.05 were imported into the IPA. a Top canonical pathways by DFX treatment in the removed tumors. Pancreatic adenocarcinoma signaling was observed. b Top upstream regulators by DFX treatment in the removed tumors; TGF- ß1 was strongly inhibited. c A heatmap of differently expressed genes in the Pancreatic Adenocarcinoma Signaling pathway. Most of the genes were downregulated after DFX treatmentBack to article page